Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data.

Abstract:

BACKGROUND:Our objectives were to develop a disease progression model for cognitive decline in Alzheimer's disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. METHODS:Placebo-controlled randomized AD clinical trials were systemically searched in public databases. Longitudinal placebo response (mean change from baseline in the cognitive subscale of the Alzheimer's Disease Assessment Scale [ADAS-cog]) and the corresponding demographic information were extracted to establish a disease progression model. Covariate screening and subgroup analyses were performed to identify potential factors affecting the disease progression rate. RESULTS:A total of 134 publications (140 trials) were included in this model-based meta-analysis. The typical disease progression rate was 5.82 points per year. The baseline ADAS-cog score was included in the final model using an inverse U-type function. Age was found to be negatively correlated with disease progression rate. After correcting the baseline ADAS-cog score and the age effect, no significant difference in the disease progression rate was found between trials published before and after 2008 and between trials using an add-on design and those that did not use an add-on design. However, a significant difference was found among different trial regions. Trials in East Asian countries showed the slowest decline rate and the largest placebo effect. CONCLUSIONS:Our model successfully quantified AD disease progression by integrating baseline ADAS-cog score and age as important predictors. These factors and geographic location should be considered when optimizing future trial designs and conducting indirect comparisons of clinical outcomes.

journal_name

Alzheimers Res Ther

authors

Zhang N,Zheng X,Liu H,Zheng Q,Li L

doi

10.1186/s13195-020-00630-5

subject

Has Abstract

pub_date

2020-05-26 00:00:00

pages

64

issue

1

issn

1758-9193

pii

10.1186/s13195-020-00630-5

journal_volume

12

pub_type

杂志文章
  • Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

    abstract:BACKGROUND:Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0477-0

    authors: Startin CM,Ashton NJ,Hamburg S,Hithersay R,Wiseman FK,Mok KY,Hardy J,Lleó A,Lovestone S,Parnetti L,Zetterberg H,Hye A,LonDownS Consortium.,Strydom A

    更新日期:2019-03-21 00:00:00

  • APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain.

    abstract:BACKGROUND:The application of advanced sequencing technologies and improved mass-spectrometry platforms revealed significant changes in gene expression and lipids in Alzheimer's disease (AD) brain. The results so far have prompted further research using "multi-omics" approaches. These approaches become particularly rel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0558-0

    authors: Lefterov I,Wolfe CM,Fitz NF,Nam KN,Letronne F,Biedrzycki RJ,Kofler J,Han X,Wang J,Schug J,Koldamova R

    更新日期:2019-12-30 00:00:00

  • The association of vascular disorders with incident dementia in different age groups.

    abstract:BACKGROUND:There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefore, the aim of the present study was to determine the association of vascular disorders with incident...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0496-x

    authors: Legdeur N,van der Lee SJ,de Wilde M,van der Lei J,Muller M,Maier AB,Visser PJ

    更新日期:2019-05-17 00:00:00

  • Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy.

    abstract:INTRODUCTION:The goal was to identify which neurochemicals differ in professional athletes with repetitive brain trauma (RBT) when compared to healthy controls using a relatively new technology, in vivo Localized COrrelated SpectroscopY (L-COSY). METHODS:To achieve this, L-COSY was used to examine five former professi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0094-5

    authors: Lin AP,Ramadan S,Stern RA,Box HC,Nowinski CJ,Ross BD,Mountford CE

    更新日期:2015-03-15 00:00:00

  • Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data.

    abstract:INTRODUCTION:There have been recent reports about a decline in dementia incidence, but only little is known about trends in the mortality of patients with dementia. Only the simultaneous analysis of both trends can inform whether the reported decline in dementia has led to a compression of dementia into higher ages. M...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0146-x

    authors: Doblhammer G,Fink A,Zylla S,Willekens F

    更新日期:2015-11-05 00:00:00

  • Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.

    abstract:INTRODUCTION:MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer's disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has been inconsistent, although insufficient power and incomplete assessment of MAPT haplotypes ma...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt268

    authors: Allen M,Kachadoorian M,Quicksall Z,Zou F,Chai HS,Younkin C,Crook JE,Pankratz VS,Carrasquillo MM,Krishnan S,Nguyen T,Ma L,Malphrus K,Lincoln S,Bisceglio G,Kolbert CP,Jen J,Mukherjee S,Kauwe JK,Crane PK,Haines JL,

    更新日期:2014-07-01 00:00:00

  • Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

    abstract:INTRODUCTION:The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial. METHODS:This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in t...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0081-2

    authors: Mori E,Ikeda M,Nagai R,Matsuo K,Nakagawa M,Kosaka K

    更新日期:2015-02-03 00:00:00

  • Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

    abstract::The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/alzrt29

    authors: Tan ZS,Seshadri S

    更新日期:2010-04-12 00:00:00

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

    abstract:INTRODUCTION:Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:We examined Clinical...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt269

    authors: Cummings JL,Morstorf T,Zhong K

    更新日期:2014-07-03 00:00:00

  • Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

    abstract:BACKGROUND:Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the predictive value of a P...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0398-3

    authors: de Wilde A,van Buchem MM,Otten RHJ,Bouwman F,Stephens A,Barkhof F,Scheltens P,van der Flier WM

    更新日期:2018-07-28 00:00:00

  • Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment.

    abstract:BACKGROUND:The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer's disease (AD) and mild cognitive impairment (MCI) using optical coherence tomography angiography (OCTA). METHODS:In this cross-sectional study, 24 AD participants, 37 MCI part...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00724-0

    authors: Chua J,Hu Q,Ke M,Tan B,Hong J,Yao X,Hilal S,Venketasubramanian N,Garhöfer G,Cheung CY,Wong TY,Chen CL,Schmetterer L

    更新日期:2020-12-04 00:00:00

  • An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

    abstract:INTRODUCTION:Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and increases in absolute concentration with serial collection. It is currently unknown what effect differ...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-015-0136-z

    authors: Lucey BP,Gonzales C,Das U,Li J,Siemers ER,Slemmon JR,Bateman RJ,Huang Y,Fox GB,Claassen JA,Slats D,Verbeek MM,Tong G,Soares H,Savage MJ,Kennedy M,Forman M,Sjögren M,Margolin R,Chen X,Farlow MR,Dean RA,Waring J

    更新日期:2015-07-29 00:00:00

  • Systemic and central nervous system metabolic alterations in Alzheimer's disease.

    abstract:BACKGROUND:Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quanti...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0551-7

    authors: van der Velpen V,Teav T,Gallart-Ayala H,Mehl F,Konz I,Clark C,Oikonomidi A,Peyratout G,Henry H,Delorenzi M,Ivanisevic J,Popp J

    更新日期:2019-11-28 00:00:00

  • Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.

    abstract:BACKGROUND:Intracerebral inoculation of extracts from post-mortem human Alzheimer's disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the synthetic peptide, in terms of amyloid-β internalization and seed and cell-to-cell transmission of cyt...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0513-0

    authors: Pedrero-Prieto CM,Flores-Cuadrado A,Saiz-Sánchez D,Úbeda-Bañón I,Frontiñán-Rubio J,Alcaín FJ,Mateos-Hernández L,de la Fuente J,Durán-Prado M,Villar M,Martínez-Marcos A,Peinado JR

    更新日期:2019-06-29 00:00:00

  • PERK: a novel therapeutic target for neurodegenerative diseases?

    abstract::Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (pro...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt260

    authors: Ma T,Klann E

    更新日期:2014-05-29 00:00:00

  • Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.

    abstract:BACKGROUND:[18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes [18F]FDG-PET a valuable tool in the diagnostic workup of neurodegenerative diseases. The utility of [18F]FDG-PET in dementia with Lewy bodies (DLB) needs further val...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0473-4

    authors: Caminiti SP,Sala A,Iaccarino L,Beretta L,Pilotto A,Gianolli L,Iannaccone S,Magnani G,Padovani A,Ferini-Strambi L,Perani D

    更新日期:2019-02-23 00:00:00

  • Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease.

    abstract:BACKGROUND:Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-related neurodegeneration. METHODS:A gene co-expression network was constructed using data obtained...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00674-7

    authors: Lancour D,Dupuis J,Mayeux R,Haines JL,Pericak-Vance MA,Schellenberg GC,Crovella M,Farrer LA,Kasif S

    更新日期:2020-09-02 00:00:00

  • Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

    abstract:BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0265-7

    authors: Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

    更新日期:2017-06-06 00:00:00

  • Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

    abstract::Symptomatic treatments for Alzheimer's disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for improving patients' comfort and reducing the burden felt by caregivers, especially those facing behavioral disorder...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt228

    authors: Ousset PJ,Delrieu J,Vellas B

    更新日期:2013-12-11 00:00:00

  • Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

    abstract:BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0170-5

    authors: Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2016-02-12 00:00:00

  • Amyloid β-protein oligomers and Alzheimer's disease.

    abstract::The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer's disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were the key etiologic agents in Alzheimer's disease. We review here the results of in vivo, in vitro and in silic...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt226

    authors: Hayden EY,Teplow DB

    更新日期:2013-11-29 00:00:00

  • Generation of a new transgenic mouse model for assessment of tau gene silencing therapies.

    abstract:BACKGROUND:Targeting the expression of genes has emerged as a potentially viable therapeutic approach to human disease. In Alzheimer's disease, therapies that silence the expression of tau could be a viable strategy to slow disease progression. METHODS:We produced a novel strain of transgenic mice that could be used t...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0202-1

    authors: Fromholt S,Reitano C,Brown H,Lewis J,Borchelt DR

    更新日期:2016-09-05 00:00:00

  • The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial.

    abstract:BACKGROUND:Synaptic dysfunction contributes to cognitive impairment in Alzheimer's disease and may be countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored whether the medical food Souvenaid affects brain phospholipid metabolism in patients with Alzheimer's dis...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/s13195-017-0286-2

    authors: Rijpma A,van der Graaf M,Lansbergen MM,Meulenbroek O,Cetinyurek-Yavuz A,Sijben JW,Heerschap A,Olde Rikkert MGM

    更新日期:2017-07-26 00:00:00

  • Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

    abstract::In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and management of patients with neurodegenerative conditions associated with deterioration of cognition. Multiple...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt199

    authors: Soucy JP,Bartha R,Bocti C,Borrie M,Burhan AM,Laforce R,Rosa-Neto P

    更新日期:2013-07-08 00:00:00

  • Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?

    abstract::Parkinson's disease, the most common movement disorder, results in an insidious reduction for patients in quality of life and ability to function. A hallmark of Parkinson's disease is the brain accumulation of neuronal cytoplasmic inclusions comprised of the protein α-synuclein. The presence of α-synuclein brain aggre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt151

    authors: Sacino AN,Giasson BI

    更新日期:2012-12-17 00:00:00

  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract:INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0090-1

    authors: Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期:2015-02-11 00:00:00

  • Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery.

    abstract::The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical devel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt159

    authors: Lane RF,Dacks PA,Shineman DW,Fillit HM

    更新日期:2013-02-04 00:00:00

  • Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

    abstract:BACKGROUND:Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. METHODS:We convened a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-017-0261-y

    authors: Grill JD,Apostolova LG,Bullain S,Burns JM,Cox CG,Dick M,Hartley D,Kawas C,Kremen S,Lingler J,Lopez OL,Mapstone M,Pierce A,Rabinovici G,Roberts JS,Sajjadi SA,Teng E,Karlawish J

    更新日期:2017-05-04 00:00:00

  • Towards a unified protocol for handling of CSF before β-amyloid measurements.

    abstract:BACKGROUND:Widespread implementation of Alzheimer's disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF). METHODS:Here, CSF collection and storage protocols were optimized for measurements of β-amyloid (Aβ)....

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0517-9

    authors: Janelidze S,Stomrud E,Brix B,Hansson O

    更新日期:2019-07-19 00:00:00

  • Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

    abstract:BACKGROUND:A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). In this context, functional magnetic resonance imaging (fMRI) may be a good candidate to detect brai...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-018-0347-1

    authors: Canu E,Sarasso E,Filippi M,Agosta F

    更新日期:2018-02-20 00:00:00